Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 11Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 190Cyclophosphamide 124Azacitidine 112Cytarabine 108fludarabine 92Specimen Handling 75Biopsy 54Daunorubicin 42Methotrexate 40Dexamethasone 37Rituximab 34blinatumomab 32Vincristine 31Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Magnetic Resonance Spectroscopy 27Whole-Body Irradiation 26obinutuzumab 25Idarubicin 25acalabrutinib 23Mycophenolic Acid 23Prednisone 22Melphalan 21Busulfan 21gilteritinib 19Stem Cell Transplantation 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Epoetin Alfa × Other hematologic neoplasm × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡